Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 with indacaterol in moderate to severe COPD
NCT01604278Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2012
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of glycopyrrolate metered dose inhaler in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Trough Forced Expiratory Volume at 1 Second at 12 weeks. Started May 2012; status: completed.
02
Drugs
glycopyrrolate metered dose inhaler
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01604278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01604278.